- November 2016
Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
- October 2016
Ruth Muschel on a new target for treatments for colorectal cancer.
- September 2016
Freddie Hamdy on the effectiveness of treatments for prostate cancer.
- August 2016
Moshe Oren discusses the effects of the microenvironment on cancer cells.
- July 2016
Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
- June 2016
Key advances in clinical trials.
- May 2016
Mark Lemmon on the underlying biochemistry of cancer.
- April 2016
Roger Stupp on using alternating electric fields as treatment.
- March 2016
Charlotte Vrinten on public perception of deaths from cancer.
- February 2016
Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
- December 2015/January 2016
Nazneen Rahman on germline genetic screening in ovarian cancer.
EJC News Focus – July/August 2013
Good times and bad for clinical trials research
Functional imaging and other new technologies are revolutionising the landscape for cancer research. The knowledge imparted by these techniques – from genetics, epigenetics, proteomics and so on – should mean that we're entering a new phase in our understanding and therefore treatment of the disease.
Yet many of the same old obstacles between lab and clinic remain. Clinical trials research is still dogged by regulatory issues, funding is a perennial problem, agreement on data protection has yet to be reached.
EORTC President Roger Stupp calls for the patient's point of view to move centre stage. While rarified discussions and debates take place, patients are waiting for clinical trials to be set up and for results to be integrated into clinical practice, he says. Here, he tells Helen Saul that speedy activation of trials is needed, as is funding for academic trials and, overall, a common sense approach which would allow the questions most relevant to patients, to be addressed.